THANK YOU FOR SUBSCRIBING
The round was driven by Hatteras Venture Partners with cooperation from Takeda Ventures, UCB Ventures, and Alexandria Venture Investments. StrideBio's Board of Directors was joined by Jayson Punwani, PhD, Partner, Takeda Ventures, and Erica Whittaker, PhD, Vice President, Head of UCB Ventures
The organization will utilize the funds move forward numerous programs towards the clinic.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
StrideBio, gives an AAV (Adeno-related infection) a vector advancement platform that utilizes structure-guided development to find novel capsids with a diminished antibody binding profile in various multiple tissues, including liver, muscle, eye and CNS, with enhanced properties for in vivo gene delivery applications.
The fundamental innovation depends on crafted by fellow benefactors, Dr. Aravind Asokan at the University of North Carolina at Chapel Hill and Dr. Mavis Agbandje-McKenna at the University of Florida.
Clay Thorp, General Partner, Hatteras Venture Partners states "StrideBio is quickly advancing towards becoming a leading gene therapy company for rare diseases," "We are excited to be accompanied by three new investors and to continue our assistance as the company rapidly grows."
Check Out Review Of CIOReview : Crunchbase, Glassdoor
Check This Out : CIOReview Overview, Muckrack
More in News